 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...162163164165166167168169170171172...235236» |
- || Avastin (bevacizumab) / Roche
Clinical, P2 data, Journal: Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study). (Pubmed Central) - Nov 21, 2019
In mCRC patients, biweekly CAPIRI + bevacizumab appears effective and feasible as a second-line chemotherapy with relatively low toxicities, and has potential as a useful substitute for FOLFIRI + bevacizumab.
- || Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date, Combination therapy, Metastases: GP28328: A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Nov 20, 2019
P1, N=240, Active, not recruiting, Sponsor: Genentech, Inc.
In mCRC patients, biweekly CAPIRI + bevacizumab appears effective and feasible as a second-line chemotherapy with relatively low toxicities, and has potential as a useful substitute for FOLFIRI + bevacizumab. Trial completion date: Aug 2019 --> Jan 2020 | Trial primary completion date: Aug 2019 --> Jan 2020
- | Oncaspar liquid (pegaspargase) / Servier
Trial completion: Treatment of Acute Lymphoblastic Leukemia in Children (clinicaltrials.gov) - Nov 20, 2019
P3, N=800, Completed, Sponsor: Dana-Farber Cancer Institute
Trial completion date: Aug 2019 --> Jan 2020 | Trial primary completion date: Aug 2019 --> Jan 2020 Active, not recruiting --> Completed
- || BNT321 / BioNTech
Trial primary completion date, Monotherapy: MV-0715-CP-001.01: Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies (clinicaltrials.gov) - Nov 20, 2019
P1, N=68, Recruiting, Sponsor: MabVax Therapeutics, Inc.
Active, not recruiting --> Completed Trial primary completion date: Dec 2018 --> Dec 2019
- | Trial completion date, Trial primary completion date: SENECA: CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas (clinicaltrials.gov) - Nov 20, 2019
P2, N=112, Recruiting, Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Trial primary completion date: Dec 2018 --> Dec 2019 Trial completion date: Jan 2021 --> Jan 2022 | Trial primary completion date: Jan 2021 --> Jan 2022
- | ondansetron / Generic mfg.
New trial: OPT-JIA: The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis (clinicaltrials.gov) - Nov 20, 2019
P=N/A, N=176, Recruiting, Sponsor: University of British Columbia
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis (clinicaltrials.gov) - Nov 20, 2019
P2, N=25, Recruiting, Sponsor: Sun Yat-sen University
- |||| Modufolin (arfolitixorin) / Isofol Medical
Clinical: Can the novel agent arfolitixorin supplant leucovorin calcium, a widely used component of combination regimens for patients with metastatic colorectal cancer? #crcsm @HH_Oncodr @RutgersCancer https://t.co/PPg7ZAgXNF (Twitter) - Nov 18, 2019
- || Vectibix (panitumumab) / Amgen
New P2 trial: FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer (clinicaltrials.gov) - Nov 18, 2019
P2, N=35, Not yet recruiting, Sponsor: Criterium, Inc.
- | New P3 trial, Metastases: GEMFOX: FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX (clinicaltrials.gov) - Nov 17, 2019
P3, N=400, Not yet recruiting, Sponsor: Assistance Publique - H
- || leucovorin calcium / generics, fluorouracil / generics, irinotecan / generics
Review, Clinical Trial,Phase I, Clinical Trial,Phase II, Journal: Are We Sure that Adjuvant Chemotherapy is the Best Approach for Resectable Pancreatic Cancer? Are We in the Era of Neoadjuvant Treatment? A Review of Current Literature. (Pubmed Central) - Nov 17, 2019
In this review, we analyze the advantages and disadvantages of the two therapeutic approaches in RPC. We need studies that compare the two approaches and can identify the appropriate sequence of adjuvant therapy after neoadjuvant treatment and surgery.
- | Viracept (nelfinavir) / ViiV Healthcare, Roche, OvaRex (oregovomab) / CanariaBio
Trial completion, Trial completion date, Metastases: Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Nov 15, 2019
P2, N=11, Completed, Sponsor: University of Nebraska
We need studies that compare the two approaches and can identify the appropriate sequence of adjuvant therapy after neoadjuvant treatment and surgery. Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Dec 2018
- | Avastin (bevacizumab) / Roche
New P1 trial, Metastases: Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab (clinicaltrials.gov) - Nov 15, 2019
P1, N=20, Not yet recruiting, Sponsor: Anne Noonan
- | Rituxan (rituximab) / Roche
Trial completion date, Trial primary completion date, Combination therapy: Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov) - Nov 15, 2019
P2, N=25, Active, not recruiting, Sponsor: University of Miami
Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Dec 2018 Trial completion date: Dec 2019 --> Sep 2021 | Trial primary completion date: Dec 2019 --> Sep 2021
- | Trial completion: A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients (clinicaltrials.gov) - Nov 15, 2019
P2, N=25, Completed, Sponsor: University of Michigan Rogel Cancer Center
Trial completion date: Dec 2019 --> Sep 2021 | Trial primary completion date: Dec 2019 --> Sep 2021 Active, not recruiting --> Completed
- | Trial completion, Metastases: S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Nov 15, 2019
P2, N=213, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Cyramza (ramucirumab) / Eli Lilly
Phase classification, Enrollment change, Trial completion date, Trial primary completion date, Metastases: RAMIRIS: Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy (clinicaltrials.gov) - Nov 15, 2019
P2/3, N=429, Active, not recruiting, Sponsor: IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest
Active, not recruiting --> Completed Phase classification: P2 --> P2/3 | N=111 --> 429 | Trial completion date: Mar 2021 --> May 2022 | Trial primary completion date: Mar 2021 --> May 2022
- | Rubraca (rucaparib) / Pharma& Schweiz, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial primary completion date, BRCA Biomarker, PARP Biomarker, Metastases: Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer (clinicaltrials.gov) - Nov 15, 2019
P2, N=110, Recruiting, Sponsor: Academic and Community Cancer Research United
Phase classification: P2 --> P2/3 | N=111 --> 429 | Trial completion date: Mar 2021 --> May 2022 | Trial primary completion date: Mar 2021 --> May 2022 Trial primary completion date: Dec 2021 --> Nov 2020
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial completion date, Trial initiation date, Combination therapy, Metastases: Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma: (clinicaltrials.gov) - Nov 15, 2019
P2, N=28, Not yet recruiting, Sponsor: Big Ten Cancer Research Consortium
Trial primary completion date: Dec 2021 --> Nov 2020 Trial completion date: Jul 2021 --> Mar 2022 | Initiation date: Oct 2019 --> Mar 2020
- |||| oleclumab (MEDI9447) / AstraZeneca, monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
New P2 trial, Combination therapy: Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC (clinicaltrials.gov) - Nov 14, 2019
P2, N=160, Not yet recruiting, Sponsor: MedImmune LLC
- | Biomarker, New P2 trial, Metastases: PRIMUS 001: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Nov 14, 2019
P2, N=500, Recruiting, Sponsor: Judith Dixon-Hughes
- || Avastin (bevacizumab) / Roche, paclitaxel / Generic Mfg.
Clinical, P1 data, Journal: Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial. (Pubmed Central) - Nov 14, 2019
The adverse events of mFOLFOX6-bevacizumab or CapeOX-bevacizumab in combination with ip PTX were considered similar to those described in previous studies of oxaliplatin-based treatment alone. 1 year after the start of chemotherapy, the efficacy of ip PTX will be evaluated as a secondary outcome.
- | New P2 trial, Metastases: POF Versus FOLFOX Plus IP Paclitaxel in AGC (clinicaltrials.gov) - Nov 14, 2019
P2, N=260, Not yet recruiting, Sponsor: Fujian Cancer Hospital
- | Trial completion date, Trial primary completion date, Metastases: BCC-RAD-13: Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer (clinicaltrials.gov) - Nov 11, 2019
P2, N=28, Recruiting, Sponsor: University of Louisville
1 year after the start of chemotherapy, the efficacy of ip PTX will be evaluated as a secondary outcome. Trial completion date: May 2018 --> May 2025 | Trial primary completion date: May 2018 --> May 2025
- | NN1213 / Novo Nordisk
Biomarker, Trial completion date, Trial primary completion date, Surgery: TRIGGER: Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker - Phase III Non CTIMP Trial (clinicaltrials.gov) - Nov 10, 2019
P2/3, N=90, Recruiting, Sponsor: Royal Marsden NHS Foundation Trust
Trial completion date: May 2018 --> May 2025 | Trial primary completion date: May 2018 --> May 2025 Trial completion date: Dec 2021 --> Dec 2026 | Trial primary completion date: Jun 2018 --> Dec 2021
- || epacadostat (INCB024360) / Incyte
Enrollment open: Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer (clinicaltrials.gov) - Nov 9, 2019
P1, N=39, Recruiting, Sponsor: Washington University School of Medicine
Trial completion date: Dec 2021 --> Dec 2026 | Trial primary completion date: Jun 2018 --> Dec 2021 Not yet recruiting --> Recruiting
- leucovorin calcium / generics
NUTRITIONAL SUPPLEMENTATION IN PATIENTS WITH COMBINED IMMUNODEFICIENCY SECONDARY TO MTHFD1 DEFICIENCY (Monitor 5) - Nov 9, 2019 - Abstract #ACAAI2019ACAAI_795;
Thus we administered oral supplementation of B12 and Leucovorin to support folate metabolism and Betaine to reduce toxicity of elevated homocysteine...IgG levels have expectedly proportionally increased, though endogenous production can only be assessed once immunologlobulin therapy is discontinued. This case supports nutritional folate supplementation in patients with combined immunodeficiency secondary to MTHFD1 deficiency.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Journal: Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. (Pubmed Central) - Nov 8, 2019
P3
A combination of encorafenib, cetuximab, and binimetinib resulted in significantly longer overall survival and a higher response rate than standard therapy in patients with metastatic colorectal cancer with the BRAF V600E mutation. (Funded by Array BioPharma and others; BEACON CRC ClinicalTrials.gov number, NCT02928224; EudraCT number, 2015-005805-35.).
- leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
Proton Pump Inhibitors Associated with Higher Incidence of Mucositis in Patients Receiving Methotrexate for Graft Vs Host Disease Prophylaxis (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_4462;
While the indications for PPI were not readily known, this study raises the question if PPIs should be discontinued or patients transitioned to a histamine blocker prior to MTX administration to improve severity of mucositis and reduce costs associated with TPN/PCA use. Additional studies are needed in order to further characterize the association of PPI with MTX and its impact on clinical outcomes.
- leucovorin calcium / Generic mfg., methotrexate / Generic mfg., Rituxan (rituximab) / Roche, Biogen
Impact of Preemptive Leucovorin Dose Escalation on Incidence of Delayed Methotrexate Elimination in Lymphoma Patients Receiving High-Dose Methotrexate (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_2455;
Rather than protective, we found that preemptively increased leucovorin doses used during subsequent cycles did not improve the incidence of delayed elimination, reduce the incidence of AKI, or shorten hospital LOS per MTX dose. Further investigation is needed to optimize dosing strategies and supportive measures following MTX administration for management of lymphoma patients.
- | Trial primary completion date: FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM (clinicaltrials.gov) - Nov 6, 2019
P3, N=160, Not yet recruiting, Sponsor: Sun Yat-sen University
Further investigation is needed to optimize dosing strategies and supportive measures following MTX administration for management of lymphoma patients. Trial primary completion date: Oct 2021 --> Oct 2022
- leucovorin calcium / generics, fluorouracil / generics
PRIMUS 002: An umbrella phase II study examining two neo-adjuvant regimens (FOLFOX-A and AG) in resectable and borderline resectable Pancreatic Ductal AdenoCarcinoma (PDAC) () - Nov 5, 2019 - Abstract #NCRI2019NCRI_436;
3 patients enrolled to date : 2 to receive FA and 1 to AG treatment. Conclution: Study ongoing
- leucovorin calcium / generics, fluorouracil / generics, irinotecan / generics
Neoadjuvant FOLFOXIRI for colorectal cancer - a single-centre retrospective study of outcomes () - Nov 5, 2019 - Abstract #NCRI2019NCRI_346;
The median age was 50 years (range 32-66). All patients had performance status 0-1.
- metformin / generics, leucovorin calcium / generics, fluorouracil / generics
The effect of combined FOLFOX with metformin in colorectal cancer cell () - Nov 5, 2019 - Abstract #NCRI2019NCRI_259;
However, no synergistic effect of metformin and FOLFOX was found in cell migration. In vivo, the metformin plus FOLFOX group had a prominent decrease of tumor volume or weight than FOLFOX-only group and metformin-only group.
- ||| Avastin (bevacizumab) / Roche
Enrollment open: QUATTRO-II: CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC (clinicaltrials.gov) - Nov 4, 2019
P2, N=112, Recruiting, Sponsor: Chugai Pharmaceutical
In vivo, the metformin plus FOLFOX group had a prominent decrease of tumor volume or weight than FOLFOX-only group and metformin-only group. Not yet recruiting --> Recruiting
- | Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Enrollment open: AALL1732: Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy (clinicaltrials.gov) - Nov 4, 2019
P3, N=3698, Recruiting, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Bylantra (devimistat) / Cornerstone Pharma
Trial completion date, Combination therapy, Metastases: CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Nov 4, 2019
P1, N=21, Active, not recruiting, Sponsor: Wake Forest University Health Sciences
Not yet recruiting --> Recruiting Trial completion date: Oct 2019 --> Jan 2020
- || monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
Trial primary completion date, IO biomarker, Metastases: A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (clinicaltrials.gov) - Nov 3, 2019
P1/2, N=501, Recruiting, Sponsor: MedImmune LLC
Trial completion date: Oct 2019 --> Jan 2020 Trial primary completion date: Oct 2021 --> Mar 2022
- ||| Opdivo (nivolumab) / BMS
Enrollment closed: RELATIVITY-060: An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers (clinicaltrials.gov) - Nov 3, 2019
P2, N=250, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Oct 2021 --> Mar 2022 Recruiting --> Active, not recruiting
- | oxaliplatin / Generic Mfg., Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen, Takeda
Retrospective data, Journal: Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: a retrospective analysis of two randomised trials. (Pubmed Central) - Nov 2, 2019
P2, P3
Maintenance of panitumumab plus 5-FU/LV after oxaliplatin discontinuation was well-tolerated, and may be an acceptable treatment paradigm for patients demonstrating a good response to first-line treatment. Prospective studies are warranted.
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment closed: ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 1, 2019
P3, N=488, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Prospective studies are warranted. Recruiting --> Active, not recruiting
- | leucovorin calcium / generics
Journal: Nutritional support in mitochondrial diseases: the state of the art. (Pubmed Central) - Oct 31, 2019
In particular, we analyze the role of Coenzyme Q10, Creatine monohydrate, α-lipoic acid, riboflavin, arginine and citrulline, folinic acid, carnitine, vitamin C, K, and E. Every attempt at nutritional intervention should be made knowing patient's disease and focusing on his/her energy and nutrients' requirements. For this reason, clinicians expert in mitochondrial medicine and clinical nutritionists should work together to ameliorate care in these fragile patients.
- | fluconazole / Generic Mfg.
Journal: Activity of base analogues (5-fluorouracil, 5-flucytosine) against planktonic cells and mature biofilm of Candida yeast. Effect of combination with folinic acid. (Pubmed Central) - Oct 31, 2019
For this reason, clinicians expert in mitochondrial medicine and clinical nutritionists should work together to ameliorate care in these fragile patients. Therapy of 5-FU+folinate is well known in cancer treatment, in this study we reveal the beneficial effect of folinate on antifungal activity of 5-FC as well as the antifungal potential of 5-FU+folinate.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma (clinicaltrials.gov) - Oct 28, 2019
P2, N=35, Recruiting, Sponsor: Yuhong Li
Therapy of 5-FU+folinate is well known in cancer treatment, in this study we reveal the beneficial effect of folinate on antifungal activity of 5-FC as well as the antifungal potential of 5-FU+folinate. Trial completion date: Dec 2018 --> Dec 2022 | Trial primary completion date: Sep 2018 --> Dec 2019
- | New P2a trial: FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer (clinicaltrials.gov) - Oct 27, 2019
P2a, N=20, Not yet recruiting, Sponsor: Jean Grem, MD
- ||| leucovorin calcium / generics
Including folinic acid deficiencies,metabolic issues & underlying genetic disorders (like X linked issues) as suggested by @AutismEnergetic I feel gut biome is a huge part of the equation but getting past the food aversions is a huge hurdle. #ASD #Encephalitis #Gutbiome (Twitter) - Oct 27, 2019
- | leucovorin calcium / generics, fluorouracil / generics
Clinical, Journal: Deep Learning-Based Survival Analysis Identified Associations Between Molecular Subtype and Optimal Adjuvant Treatment of Patients With Gastric Cancer. (Pubmed Central) - Oct 25, 2019
Our SRN predicted survival at a high rate, reaching 92% at postoperative year 5. Our findings suggest that SRN-based clinical trials or risk-adapted adjuvant trials could be considered for patients with GC to investigate more individualized adjuvant treatments after curative gastrectomy.
- | Folotyn (pralatrexate) / Aurobindo
Clinical, Journal: Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate. (Pubmed Central) - Oct 24, 2019
Our findings suggest that SRN-based clinical trials or risk-adapted adjuvant trials could be considered for patients with GC to investigate more individualized adjuvant treatments after curative gastrectomy. No abstract available
- ||| leucovorin calcium / generics
Clinical: This is the regimen he’s on now (pyrimethamine 25 + Atovaquone 1500), but I can increase the dose of leucovorin and hope for an increase in CD4. My conclusion: someone needs to do a study on stopping toxo prophylaxis in virologically suppressed patients with cd4 100-200. (Twitter) - Oct 24, 2019
- | leucovorin calcium / generics, fluorouracil / generics
Journal: Physiological and pathophysiological significance of vitamin B. Summary on the occasion of the 30-year introduction of folic acid as a dietary supplement (Pubmed Central) - Oct 24, 2019
Orv Hetil. 2019; 160(28): 1087-1096.